Statins in acute coronary syndromes

This review article provides results of recent studies (ARMYDA, NAPLES II, MIRACL, ARMYDA-ACS, JUPITER, LUNAR) with the use of inhibitors of HMG CoA reductase (statins) in patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention. Based on the results of these clinical and experimental studies, lipid-lowering, anti-inflammatory and various other pleiotropic effects of statin therapy in acute forms of coronary heart disease have been proved. Also, the authors presented the main results and conclusions on the studies conducted in our center to study the effect of statins on the stunned myocardium, reperfusion injury of the myocardium in acute myocardial infarction.